Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling
- Design
- Animal study · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Not human evidenceVERY_INDIRECT: male mice on a high-fat, high-fructose diet and macrophage and liver cell lines; no human participants.
- Could weight loss explain it?
- PossiblyTirzepatide improved metabolic dysfunction in the mice, and the abstract reports no weight data or analysis separating the liver effect from metabolic change; the Dectin-1 knockdown tests a signalling pathway, not weight loss.
- Study tier
- Study tier 4VERY_LOW: preclinical mouse and cell-line study.
- Assessment
- Version 2 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
In male mice with fatty liver disease brought on by a high-fat, high-fructose diet, 7 weeks of tirzepatide improved liver fat, liver injury and inflammation, and lowered a macrophage inflammatory pathway (Dectin-1/Syk/NF-κB); cell experiments supported the same pathway. The abstract gives no group sizes or numerical results. This is animal and cell work and does not show the same effect in people.
01Findings
What the study reported
- Drugs
- Tirzepatide
- Route
- subcutaneous
- Dose
- 10 nmol/kg every 3 days
- Comparator
- not reported in abstract
- Treatment duration
- 7 weeks
- Primary outcome
- diet-induced hepatic steatosis and inflammation (MASLD) in mice, and the role of macrophage Dectin-1/Syk/NF-κB signalling
- Effect
- Tirzepatide improved diet-induced metabolic dysfunction, liver injury, hepatic steatosis and inflammation in mice and reduced Dectin-1/Syk/NF-κB signalling; Dectin-1 knockdown itself reduced inflammation and left a smaller additional response to tirzepatide; no numbers reported
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- Preclinical mouse and cell-line study with no group sizes or numerical results in the abstract; the authors say the macrophage signalling pathway only potentially contributes to the effect.
Who was studied
- Sex distribution
- male mice only
- Obesity status
- not reported in abstract
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- high-fat, high-fructose diet-induced MASLD (mouse model)
Study quality details
- Study design
- Preclinical (animal)
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- mixed
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- VERY_INDIRECT
- Statistical precision
- no CI reported; no p values or group sizes reported
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- The authors declare no known competing financial interests or personal relationships that could have influenced the work.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear. This study investigated the protective effects of tirzepatide against high-fat, high-fructose diet (HFHFD)-induced MASLD and examined the potential involvement of macrophage Dectin-1/spleen tyrosine kinase (Syk)/nuclear factor-κB (NF-κB) signaling. After 7 weeks of HFHFD feeding to establish the MASLD model, male C57BL/6J mice received tirzepatide (10 nmol/kg, subcutaneously, every 3 days) for an additional 7 weeks. Biochemical assays, histology, hepatic RNA sequencing (RNA-seq), RT-qPCR, Western blotting, and immunofluorescence were performed. Palmitic acid (PA)-stimulated RAW264.7 cells, siRNA-mediated Dectin-1 knockdown, and a RAW264.7 cell-derived conditioned medium-based macrophage-hepatocyte indirect interaction model were used for mechanistic validation. Tirzepatide treatment improved HFHFD-induced metabolic dysfunction, liver injury, hepatic steatosis, and inflammatory responses in mice. RNA-seq revealed enrichment of C-type lectin receptor and NF-κB signaling pathways, while HFHFD-induced Clec7a upregulation was reversed by tirzepatide. Tirzepatide reduced hepatic macrophage accumulation, Dectin-1 expression, and Syk/p65 phosphorylation. In PA-stimulated RAW264.7 cells, tirzepatide suppressed pro-inflammatory cytokine expression and secretion and inhibited Dectin-1/Syk/NF-κB activation. Conditioned medium from tirzepatide-treated RAW264.7 cells attenuated lipid accumulation and abnormalities in lipid metabolism- and inflammation-related gene expression in HepG2 cells. Dectin-1 knockdown itself attenuated PA-induced inflammatory responses and was associated with a reduced additional response to tirzepatide. These findings suggest that tirzepatide alleviates HFHFD-induced MASLD, with suppression of macrophage Dectin-1/Syk/NF-κB signaling potentially contributing to these effects.